close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Metsera, Inc. - Common Stock (NQ:MTSR)

53.01 +0.04 (+0.08%)
Streaming Delayed Price Updated: 2:22 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Metsera, Inc. - Common Stock

< Previous 1 2 3 Next >
Down 44%, Should You Buy the Dip on Viking Therapeutics?
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly. 
Via The Motley Fool
Where Will Pfizer Be in 5 Years?
Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past. 
Via The Motley Fool
Topics Intellectual Property World Trade
Down 50%, Should You Buy the Dip on Pfizer?
Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows. 
Via The Motley Fool
Topics Intellectual Property
3 Reasons to Buy Pfizer Stock Now
After years of underperformance, the future is looking brighter for the drugmaker. 
Via The Motley Fool
Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalysts
Via Stocktwits
2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 in October
You don't need to be rich to put your money to work on Wall Street. 
Via The Motley Fool
Topics Intellectual Property
3 Things You Need to Know if You Buy Pfizer Today
Pfizer has an attractive 7.2% dividend yield, but there are some pros and cons you need to understand before you buy it. 
Via The Motley Fool
Topics Intellectual Property
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
These stocks could see growth take off over the next few years. 
Via The Motley Fool
Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial
Metsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global Phase 3 program in 2025. 
Via Benzinga
Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out
The company recently announced an acquisition that will bolster its growth prospects in the GLP-1 obesity market. 
Via The Motley Fool
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Right now, these dividend payers are top options for folks who like to set it and forget it. 
Via The Motley Fool
Topics Artificial Intelligence Economy
Down 55%, Should You Buy the Dip on Pfizer?
Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track. 
Via The Motley Fool
Topics Intellectual Property
Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?
The company continues to improve its pipeline. 
Via The Motley Fool
Pfizer is Locking in New Growth Through a New Acquisition
Pfizer is undergoing a new acquisition, exposing it to the weight loss market and additional revenue growth potential, which isn't priced in yet. 
Via MarketBeat
Topics Artificial Intelligence
Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock?
The pharmaceutical giant is again plunging headfirst into weight-loss drug development. 
Via The Motley Fool
Topics Intellectual Property
2 Top Passive Income Stocks to Buy Now
These dividend stocks offer high yields and growth catalysts that could support payouts for decades. 
Via The Motley Fool
Topics Bonds Economy Lawsuit
What's Pfizer Getting in Its $7.3 Billion Metsera Buyout?
Pfizer's plan to enter the booming obesity market took an expensive new turn. 
Via The Motley Fool
Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’
BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality. 
Via Stocktwits
Top stock movements in today's session.
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Nvidia, Metsera, Oracle, Apple, Compass: Stocks Making The Biggest Moves Today
Via Stocktwits
Why Pfizer Stock Just Popped
Pfizer's own GLP-1 drug candidate failed earlier this year -- so it's buying someone else's. 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Top movers analysis in the middle of the day on 2025-09-22: top gainers and losers in today's session.
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Gold Gains Over 1%; Quantum Computing Shares Plunge
 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
PROS Holdings, MBX Biosciences, Metsera, Anywhere Real Estate And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Pfizer Claws Deeper Into The Obesity Space With $4.9 Billion Metsera Deal
The deal follows two high-profile failures for Pfizer, which is trying to broaden its small pipeline in weight loss. 
Via Investor's Business Daily
Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal
Pfizer will buy Metsera for $4.9 billion plus milestone payments, adding incretin, amylin, and oral obesity drug candidates to its pipeline. 
Via Benzinga
Monday's pre-market session: top gainers and losers
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today